143300-67-8

Basic information

• Product Name: Ethyl 3-oxo-3-[(3-ethoxy-3-oxopropyl)aMino]propanoate
• Synonyms: Ethyl 3-oxo-3-[(3-ethoxy-3-oxopropyl)aMino]propanoate;NSC 134465
• CAS NO: 143300-67-8
• Molecular Formula: C₁₀H₁₇NO₅
• Molecular Weight: 231.24568
• Mol File: 143300-67-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 3-oxo-3-[(3-ethoxy-3-oxopropyl)aMino]propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-oxo-3-[(3-ethoxy-3-oxopropyl)aMino]propanoate(143300-67-8)
• EPA Substance Registry System: Ethyl 3-oxo-3-[(3-ethoxy-3-oxopropyl)aMino]propanoate(143300-67-8)

Safety Data

• Hazardous Substances Data: 143300-67-8(Hazardous Substances Data)

Upstream product

• 55552-69-7 2-ethylmalonyl dichloride 
• 4244-84-2 ethyl β-alaninate hydrochloride 
• 924-73-2 3-amino-propionic acid ethyl ester 
• 36239-09-5 ethyl chlorocarbonylacetate 

Downstream Products

• 50607-30-2 piperidine-2,4-dione 

Relevant articles and documents

Furo-3-carboxamide derivatives and methods of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R1, Z1, Z2, and n are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by Tropomysin receptor kinases (Trk). Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Synthesis and biological evaluation of 5-carbamoyl-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors

5-Carbamoyl-2-phenylpyrimidine derivative 2 has been identified as a phosphodiesterase 4 (PDE4) inhibitor with moderate PDE4B inhibitory activity (IC50 = 200 nM). Modification of the carboxylic acid moiety of 2 gave N-neopentylacetamide derivative 10f, which had high in vitro PDE4B inhibitory activity (IC50 = 8.3 nM) and in vivo efficacy against lipopolysaccharide (LPS)-induced pulmonary neutrophilia in mice (ID50 = 16 mg/kg, ip). Furthermore, based on the X-ray crystallography of 10f bound to the human PDE4B catalytic domain, we designed 7,8-dihydro-6H-pyrido[4,3-d] pyrimidin-5-one derivative 39 which has a fused bicyclic lactam scaffold. Compound 39 exhibited excellent inhibitory activity against LPS-induced tumor necrosis factor alpha (TNF-α) production in mouse splenocytes (IC 50 = 0.21 nM) and in vivo anti-inflammatory activity against LPS-induced pulmonary neutrophilia in mice (41% inhibition at a dose of 1.0 mg/kg, i.t.).

In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II

Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC50 50

INDOLONE MODULATORS OF 5-HT3 RECEPTOR

The present invention relates to new indolone modulators of 5-HT3 receptor, pharmaceutical compositions thereof, and methods of use thereof.

ISOQUINOLINOPYRROLOPYRIDINONES ACTIVE AS KINASE INHIBITORS

Heteroarylpyridinone derivatives represented by formula (I) wherein R1, R2, R3, R4, R5, and X are as defined in the specification, compositions thereof, and methods of use thereof. Particularly, there are described isoquinolinoyrrolopyridinones, pharmaceutical compositions comprising them and their use as therapeutic agents in the treatment of cancer and cell proliferation disorders.

N-substituted pyrrolopyridinones active as kinase inhibitors

Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

Dihydronaphthyridine potassium channel openers

Compounds of formula I are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.